Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 08/29 10:00:00 pm
107.95 USD   -0.77%
08/29 CELGENE CORPORA : to Webcast at Upcoming Investor Conferences and R&..
08/17 CELGENE : Olympic Swimmer and Author Dara Torres Teams Up With Celge..
08/15 CELGENE : Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Offic..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : Celgene's Profits Fall, But Focus Remains on Pipeline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2013 | 07:47pm CEST

--Celgene's Q4 net falls, while revenues rise

--FDA approval decision for multiple myeloma drug Pomalyst expected in February

--Celgene shares down 2.4% to $97.64 so far this week as investors take profits

(Updates throughout adding details and analyst comment.)

 
   By Joseph Walker and Melodie Warner 
 

Celgene Corp.'s (CELG) fourth-quarter earnings fell 36% as restructuring costs and other special items hurt the drug maker's margins and masked its increased revenue.

The results had been expected since the Summit, N.J., company pre-announced full-year results for 2012 and 2013 guidance at an investor meeting earlier this month.

Celgene's revenues jumped 13% to $1.45 billion in the quarter, largely on the strength of its core blood-cancer drug franchise, which includes the blockbuster Revlimid treatment.

However, investor attention has been focused on the company's late-stage product pipeline, which includes what Celgene says are three "potential blockbusters" that would expand the company's portfolio into new disease areas.

The first of those drugs likely to reach the market is Pomalyst, a treatment for the patients with relapsed multiple myeloma, a bone marrow cancer. The U.S. Food and Drug Administration is scheduled to make an approval decision by Feb. 10. Celgene said it would launch the drug shortly after approval.

"Our commercial and medical affairs teams are ready to launch and support the thousands of patients who have exhausted all existing myeloma therapies," Celgene Executive Vice President Mark Alles said. "Successfully launching Pomalyst is a major corporate objective and we are ready."

Celgene shares fell 0.6% to $97.64, and are down 2.4% so far this week as investors take profits. Even with the recent slide, the stock has soared 24% in 2013, as investors have placed a high premium on the company's pipeline.

Celgene also plans to seek FDA approval for apremilast, a treatment for the skin disease Psoriasis, and its cancer drug Abraxane for patients with pancreatic cancer this year. Both drugs are projected to be generate billions of dollars annually for Celgene.

The new drugs are part of Celgene's strategy to expand beyond its core hematology franchise and build out new product lines in cancer to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $263.1 million, or 61 cents a share, down from $410.2 million, or 91 cents, a year earlier. Excluding items such as stock-based compensation, acquisition and restructuring costs, adjusted per-share earnings rose to $1.32 from $1.05 a year ago.

Analysts polled by Thomson Reuters had forecast earnings of $1.31 a share on revenue of $1.46 billion.

Revlimid sales jumped 17% to $1 billion, while Vidaza sales climbed 14% to $216 million.

Gross margin fell to 22.2% from 31.5% as costs rose because of preparations for the launches of Abraxane for non-small-cell lung cancer and Pomalyst. Abraxane received FDA approval for that indication in October.

Write to Joseph Walker at joseph.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
08/29 CELGENE CORPORATION : to Webcast at Upcoming Investor Conferences and R&D Deep D..
08/18 CELGENE : Patent Issued for Mutant-Selective EGFR Inhibitors and Uses (USPTO 940..
08/17 CELGENE : Olympic Swimmer and Author Dara Torres Teams Up With Celgene to Launch..
08/15 CELGENE : Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgen..
08/05 BETTERINVESTING : Magazine Releases October Stock To Study And Undervalued Stock..
08/04 CELGENE : and LYSARC Provide Update on the Phase III 'REMARC' Study of REVLIMID®..
07/29DJSanofi Profit Down as Diabetes Drug Sales Slip
07/28 CELGENE : DE/ Management's Discussion and Analysis of Financial Condition and Re..
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More news
Sector news : Bio Therapeutic Drugs
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/25 Siponimod Rides To Novartis' Rescue
08/25 Shocked! Mylan, Biotechs Swoon After Hillary's Statement
08/24 INSIDERINSIGHTS.COM DAILY ROUND UP 8 : Advance Auto Parts, Flowers Foods, AC Con..
08/23 Who's Next After Medivation?
08/23 Janssen submits application in Europe for expanded use of Darzalex
Advertisement
Financials ($)
Sales 2016 11 080 M
EBIT 2016 5 779 M
Net income 2016 3 415 M
Debt 2016 7 253 M
Yield 2016 -
P/E ratio 2016 27,11
P/E ratio 2017 19,21
EV / Sales 2016 8,26x
EV / Sales 2017 6,81x
Capitalization 84 325 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 138 $
Spread / Average Target 27%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-9.16%84 325
AMGEN, INC.5.94%128 696
GILEAD SCIENCES, INC.-21.17%105 269
REGENERON PHARMACEUTIC..-25.77%42 431
VERTEX PHARMACEUTICALS..-22.84%24 057
ACTELION LTD17.62%18 205
More Results